Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0000950170-24-121025
Filing Date
2024-11-05
Accepted
2024-11-04 20:21:08
Documents
7
Period of Report
2024-11-04

Document Format Files

Seq Description Document Type Size
1 6-K sndl-6-k-2024_q3.htm 6-K 20059
2 FS sndl-ex99_1.htm EX-99.1 2169298
3 MD&A sndl-ex99_2.htm EX-99.2 1194423
4 CEO sndl-ex99_3.htm EX-99.3 22765
5 CFO sndl-ex99_4.htm EX-99.4 22990
6 GRAPHIC img260723042_0.jpg GRAPHIC 4488
7 GRAPHIC img261646563_0.jpg GRAPHIC 4488
  Complete submission text file 0000950170-24-121025.txt   3443338
Mailing Address 919 11 AVENUE SW SUITE 300 CALGARY A0 T2R1P3
Business Address 919 11 AVENUE SW SUITE 300 CALGARY A0 T2R1P3 14039485227
SNDL Inc. (Filer) CIK: 0001766600 (see all company filings)

EIN.: 000000000 | State of Incorp.: A0 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39005 | Film No.: 241425271
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)